Increase of Nerve Regeneration Capacity by New Neurotrophic Pyrimidine Derivative MS-430

1. We studied whether a new neurotrophic pyrimidine compound, MS-430, can increase the regeneration length of the transected sciatic nerve in a silicone chamber gap of 14 mm. 2. The average length of regenerated myelinated axons in ten cases was 9.0±0 mm in the control group, 2.8±1.9 mm in the 1 mg/...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	General pharmacology 1998-11, Vol.31 (5), p.821-824
Hauptverfasser:	Noda, Masayuki, Ochi, Mitsuo, Ikuta, Yoshikazu, Awaya, Akira
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Axons - drug effects Axons - physiology Biological and medical sciences Female Medical sciences Miscellaneous MS-430 Myelin Sheath - drug effects Myelin Sheath - physiology Nerve Regeneration - drug effects Neuropharmacology new drug Peripheral nerve Pharmacology. Drug treatments pyrimidines Pyrimidines - pharmacology Rats Rats, Wistar regeneration capacity sciatic nerve Sciatic Nerve - drug effects Sciatic Nerve - physiology Sciatic Nerve - ultrastructure
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	1. We studied whether a new neurotrophic pyrimidine compound, MS-430, can increase the regeneration length of the transected sciatic nerve in a silicone chamber gap of 14 mm. 2. The average length of regenerated myelinated axons in ten cases was 9.0±0 mm in the control group, 2.8±1.9 mm in the 1 mg/kg/day of the MS-430 group and 5.0±5.1 mm in the 3 mg/kg/day of the MS-430 group, indicating that the average length was significantly larger in the 3-mg group than that in the control group ( P
ISSN:	0306-3623 1879-0011
DOI:	10.1016/S0306-3623(98)00005-6